Stroke (Strokes)

28059  relevant articles (2080 outcomes, 5404 trials/studies) found for this Disease

Strokes; Apoplexy; Stroke, Acute; Acute Stroke; Stroke, Cerebral; CVA (Cerebrovascular Accident); Cerebrovascular Accident, Acute; Cerebrovascular Stroke; Acute Cerebrovascular Accident; Acute Cerebrovascular Accidents; Acute Strokes; Apoplexy, Cerebrovascular; Brain Vascular Accident; Brain Vascular Accidents; CVAs (Cerebrovascular Accident); Cerebral Strokes; Cerebrovascular Accidents; Cerebrovascular Accidents, Acute; Cerebrovascular Strokes; Stroke, Cerebrovascular; Strokes, Acute; Strokes, Cerebral; Strokes, Cerebrovascular; Vascular Accidents, Brain; Cerebral Stroke; Cerebrovascular Accident; Cerebrovascular Apoplexy; Vascular Accident, Brain

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Myocardial Infarction
2.	Stroke (Strokes)
3.	Atrial Fibrillation
4.	Hypertension (High Blood Pressure)
5.	Carotid Stenosis (Carotid Artery Stenosis)

Experts

1.	Chopp, Michael: 33 articles (10/2008 - 08/2002)
2.	Diener, Hans-Christoph: 25 articles (09/2008 - 05/2002)
3.	Montaner, Joan: 23 articles (10/2008 - 02/2003)
4.	Hankey, Graeme J: 23 articles (06/2008 - 03/2002)
5.	Lees, Kennedy R: 22 articles (09/2008 - 12/2002)
6.	Koudstaal, P J: 21 articles (01/2006 - 01/2000)
7.	Alvarez-Sabín, José: 20 articles (10/2008 - 12/2002)
8.	Grotta, James C: 20 articles (09/2008 - 01/2002)
9.	Molina, Carlos A: 19 articles (10/2008 - 02/2003)
10.	Sacco, Ralph L: 19 articles (09/2008 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Stroke:

1.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/01/1999 - "Future studies should include an examination of those agents that have previously demonstrated efficacy in secondary stroke prevention, most notably, aspirin" 10/01/2000 - "Using the best estimate of the efficacy of aspirin to prevent first-time stroke and MI, PTOT and DA treatment recommendations whether or not to take aspirin were discordant for 38% of participants (16 of 42) (p < 0.001)" 10/01/2000 - "Finally, based on these treatment thresholds, using the best estimates of the efficacy of aspirin to prevent first-time stroke and MI, PTOT and DA treatment recommendations for individual participants were compared" 06/01/2000 - "RESULTS: There was a highly significant reduction of 7 per 1000 (SD 1) in recurrent ischemic stroke (320 [1.6%] aspirin versus 457 [2. 3%] control, 2P<0.000001) and a less clearly significant reduction of 4 (SD 2) per 1000 in death without further stroke (5.0% versus 5. 4%, 2P=0.05)" 10/01/1997 - "Aspirin appears to be most effective in younger individuals or those considered to be at low risk for stroke" Order ALL the reference details at left...
2.	Tissue Plasminogen Activator (Alteplase)FDA Link 01/01/2005 - "Evidence from randomized clinical trials indicates that systemic administration of recombinant tissue plasminogen activator (rtPA) is a highly effective treatment for acute ischemic stroke, provided that treatment is administered within the first 3 h after stroke onset" 11/01/2002 - "However, the Cochrane systematic review of thrombolysis for acute ischaemic stroke suggests that alteplase is the most promising treatment for acute ischaemic stroke" 05/01/2002 - "Intravenous thrombolysis with tissue plasminogen activator is currently the most effective treatment of acute ischemic stroke if administerd within 3 hours after symptom onset" 01/01/2008 - "Intravenous tissue plasminogen activator is the only drug proven to be effective in stroke; it is approved for administration within a 3-hour window" 03/15/2007 - "BACKGROUND: The administration of tissue plasminogen activator (t-PA) has been proven effective for ischemic stroke within 3 h after onset" Order ALL the reference details at left...
3.	Warfarin (Coumadin)FDA LinkGeneric 01/01/2008 - "summary, warfarin is highly effective in preventing ischaemic strokes in White patients with AF at a modestly higher risk of ICH" 08/01/2007 - "Anticoagulation is highly effective for stroke prevention in patients with AF, but a substantial number of patients are unable to sustain chronic therapy with warfarin" 06/01/2000 - "Adjusted-dose warfarin(target INR 2.0-3.0) is highly efficacious for preventing stroke in AF patients, and is safe for selected patients" 01/01/2000 - "Adjusted-dose warfarin (target International Normalized Ratio 2-3) is highly efficacious for prevention of stroke in patients with AF (about 60% reduction) and is relatively safe for selected patients, if carefully monitored" 09/01/1998 - "Adjusted-dose warfarin (target International Normalized Ratio [INR] 2-3) is highly efficacious for preventing stroke in AF patients (about 70% risk reduction) and is safe for selected patients, if carefully monitored" Order ALL the reference details at left...
4.	PerindoprilFDA Link 07/01/1997 - "The PROGRESS ("Perindopril Protection Against Recurrent Stroke Study") study has been designed and is under way to collect information on this important issue of the antihypertensive treatment, its purpose being to evaluate the blood pressure lowering effects with an ACE-inhibitor on recurrent stroke in an overall population of 6000 patients with a positive history of previous cerebral ischemic attacks or stroke." 06/01/2006 - "METHODS: The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, placebo-controlled trial that established the beneficial effects of BP lowering in 6105 patients with cerebrovascular disease" 10/01/2005 - "METHODS: This study was a subsidiary analysis of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS)--a randomized, placebo-controlled trial that established the beneficial effects of blood pressure--lowering in a heterogeneous group of patients with cerebrovascular disease" 01/01/2001 - "Perindopril 4 to 8 mg once daily significantly decreased carotid-femoral aortic pulse wave velocity (PWV), improved arterial compliance, reduced left ventricular mass index and, in patients with recent cerebral ischaemia and/or stroke, preserved cerebral blood flow despite significantly reducing SBP and DBP" 12/01/1996 - "CONCLUSION: Chronic treatment with perindopril is beneficial for the prevention of stroke in SPSHR, through the preservation of the myogenic response properties of the cerebral arteries, and the attenuation of tissue damage in the brain and kidneys." Order ALL the reference details at left...
5.	clopidogrel (Plavix)FDA LinkGeneric 09/14/2005 - "Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23)" 01/01/2003 - "The MATCH trial is currently being conducted to test the hypothesis that long-term administration of clopidogrel on top of ASA is superior to clopidogrel alone for the reduction of major ischaemic events in patients with recent TIA or ischaemic stroke who are at high risk of atherothrombotic recurrence" 07/01/2006 - "Clopidogrel has not shown significant reduction in reoccurrence of stroke and has not been studied for patients with a previous TIA" 11/01/2006 - "A prediction model which allows to identify patients in whom clopidogrel or dipyridamol plus ASA is superior to ASA for the secondary prevention of stroke is presented." 05/01/2005 - "A prediction model is presented which allows the identification of patients in whom clopidogrel is superior to ASA for the secondary prevention of stroke" Order ALL the reference details at left...
6.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 10/01/2003 - "Although antiplatelet agents have not proved to be beneficial in the primary prevention of stroke, they are recommended in patients with ICS in order to lower the risk of heart attack associated with this pathology" 01/01/2008 - "Certain combination therapies appear to be more effective for secondary prevention of stroke or TIA than therapy with single antiplatelet agents" 03/01/2004 - "OBJECTIVE: To provide an overview of the impact of ischemic stroke and the steps that can be taken to reduce its burden through greater awareness of the disease, improved diagnosis and better treatment, with emphasis on the use of antiplatelet agents" 05/01/2004 - "Antiplatelet agents are effective for secondary prevention after ischemic stroke, although they do not always prevent recurrent events" 01/01/1999 - "The antiplatelet agents tested to date are effective in secondary but not primary prevention of stroke" Order ALL the reference details at left...
7.	Dipyridamole (Persantine)FDA LinkGeneric 09/15/1998 - "The sustained release dipyridamole produced a significant risk reduction of 16% for stroke, 15% for stroke and/or death but no significant reduction of mortality" 07/01/2008 - "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition" 07/01/2008 - "OBJECTIVE: The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention" 07/01/2008 - "CONCLUSION: Based on the results from these 2 large, randomized trials, ASA + dipyridamole was more effective than ASA monotherapy as first-line therapy for secondary stroke prevention in these patients with a history of minor stroke or TIA of noncardioembolic etiology." 06/01/2008 - "Two large clinical trials have established the superiority of the combination of ASA and extended-release dipyridamole (ASA/ERDP) over ASA alone in patients with recent noncardioembolic ischemic stroke or TIA" Order ALL the reference details at left...
8.	Ticlopidine (Ticlid)FDA LinkGeneric 03/01/1996 - "Thus, ticlopidine is effective in reducing the risk of recurrent cerebral ischaemia and stroke" 10/01/1993 - "Ticlopidine may also be effective in reducing the risk of recurrent stroke in patients who have had a completed thromboembolic stroke." 10/01/1993 - "Two large, multicenter trials have shown that ticlopidine is effective in reducing the risk of fatal and nonfatal stroke in both men and women" 06/01/1992 - "CONCLUSIONS: Ticlopidine is effective for both primary and secondary stroke prevention" 09/01/1991 - "In contrast, major stroke prevention trials using ticlopidine have demonstrated equal benefit in women and in men" Order ALL the reference details at left...
9.	AnticoagulantsIBA 02/23/1995 - "Anticoagulants are highly effective for preventing cardioembolic stroke, but their effectiveness in non-cardioembolic stroke is uncertain because of lack of trial data" 09/01/2008 - "Antiplatelet therapy is highly effective in reducing the risk of recurrent vascular events and is recommended over oral anticoagulants for non-cardioembolic stroke" 02/01/2000 - "Further studies examining the efficacy of anticoagulants in different stroke subgroups will be necessary in order to clarify optimal clinical practice." 05/01/1997 - "There were significantly more Osler positives among those who responded positively to 'Have you had a stroke?' (P = 0.007) and 'Are you taking anticoagulants' (P = 0.044) than among those who responded negatively to these questions" 07/26/2003 - "THE CONTEXT: The demonstration of the efficacy of oral anticoagulants in the secondary prevention of ischemic stroke represents a major progress in medicine in the last twenty years" Order ALL the reference details at left...
10.	Heparin (Liquaemin)FDA LinkGeneric 01/01/2008 - "CONCLUSIONS: The results of recent studies showing an advantage of the very early administration of heparin (<3 h from stroke onset) should encourage clinicians to perform further trials on the efficacy of an early administration of heparin in acute cardioembolic stroke." 01/01/1990 - "A meta-analysis of twenty trials of intravenous or subcutaneous heparin in AMI performed during the prethrombolysis period indicated a significant reduction in mortality, reinfarction, and stroke in treated patients" 05/16/2001 - "The treatment with heparin and the selective fibrinolysis no show good results, for this reason the local intra-arterial fibrinolysis appear as the choice treatment in patients with stroke and a agiography with basilar artery occlussion or intracranial vertebral artery occlusion" 04/22/1998 - "CONTEXT: Anticoagulation with unfractionated heparin is used commonly for treatment of acute ischemic stroke, but its use remains controversial because it has not been shown to be effective or safe" 05/01/1993 - "Heparin may be effective in preventing further cardioembolic stroke or in treating stroke in progress" Order ALL the reference details at left...

Therapies and Procedures

1.	Carotid Endarterectomy 07/01/1993 - "In those areas where studies are complete, carotid endarterectomy has been shown to be highly effective in reducing stroke risk" 06/01/2003 - "PURPOSE: The efficacy of carotid endarterectomy (CEA) for prevention of stroke has been demonstrated in randomized trials; however, the optimal approach in patients excluded from these trials or who have other significant comorbid conditions remains controversial, particularly with the advent of percutaneous interventions" 11/01/2007 - "OBJECTIVE: Although carotid endarterectomy (CEA), the gold standard in stroke prevention, has been performed in the late stage after the insult, its optimal timing remains unclear" 08/01/1988 - "Additionally, carotid endarterectomy does not render complete protection against stroke and the follow-up curves for the respective treatments do not differ meaningfully, even during longterm observation" 05/01/2007 - "Although carotid endarterectomy is effective in reducing this stroke risk, it is frequently not applied within the time window for significant benefit" Order ALL the reference details at left...
2.	Thrombolytic Therapy 01/01/1993 - "CONCLUSIONS: Emergency cerebral angiography, which can be carried out relatively safely, adds important information about the nature and extent of the arterial occlusions, and the recanalization efficacy of fibrinolytic therapy for patients with acute stroke" 05/01/2008 - "BACKGROUND AND PURPOSE: Results of our recent pilot clinical trial suggest that the efficacy of thrombolytic therapy in acute ischemic stroke may be enhanced by the coadministration of high-dose albumin" 09/01/2003 - "RESULTS: Helicopter transport of acute stroke patients to tertiary care centers for thrombolytic therapy costs $35,000 per additional good outcome and $3,700 per QALY for the reference case" 01/01/2003 - "For patients treated within three hours of stroke, thrombolytic therapy appeared more effective in reducing death or dependency (OR 0.66, 95% CI 0.53 to 0.83) with no statistically significant adverse effect on death (OR 1.13, 95% CI 0.86 to 1.48)" 05/01/2000 - "This strategy is associated with a significant reduction in the incidence of reinfarction and the combined clinical end-point of death/reinfarction/stroke at 30 days when compared to standard thrombolytic therapy at the community hospital." Order ALL the reference details at left...
3.	Activities of Daily Living (ADL) 01/01/2007 - "RESULTS: The results revealed severe stroke impact and low functioning in activities of daily living in the participant group, yet the level of participation in leisure activities improved significantly after attending the program (t=-8.1, p=0.000)" 04/01/2002 - "Brief periods between stroke and onset of rehabilitation and longer duration of rehabilitation treatment were significantly associated with better outcome with respect to ADL-functions." 11/01/2000 - "Medical/surgical patients were more likely to recover premorbid ADL function (P < .05) but 1-year mortality was significantly greater (30% vs. 14% hip fracture; 18% stroke; P < .001)" 04/01/1999 - "CONCLUSIONS: Children and adolescents who survive stroke have good outcome for mobility and ADL skills, but more difficulty with language and cognitive recovery" 05/01/1993 - "According to the results of the assessment, the stroke patients' motivation remained stable when assessed two to three times during the hospital stay, whereas their UE/LE Brunnstrom stage scores and activities of daily living skill (ADL) improved significantly" Order ALL the reference details at left...
4.	Transplantation (Transplant Recipients) 09/01/2008 - "Most importantly, transplantation of Ngn1-expressing MSCs in the animal stroke model dramatically improved motor functions compared with the parental MSCs" 10/03/2008 - "Mesenchymal stem cells transplantation could be beneficial for treatment of experimental ischemic stroke in rats." 01/01/2006 - "In particular, the limitations of current stroke treatments and management reveal an urgent need to examine the efficacy of experimental treatments, such as neural transplantation, in order to develop better treatment therapies" 07/01/2005 - "Transplantation of cultured neuronal cells has been shown to be safe and effective in animal models of stroke and safe in a Phase 1 human trial" 06/01/2002 - "The pressure-volume analysis showed improvement (P <.05) in end-systolic elastance and preload recruitable stroke work in the transplantation group relative to the control group" Order ALL the reference details at left...
5.	Aftercare (After-Treatment) 09/01/2001 - "All patients showed marked improvement in their National Institutes for Health Stroke Scale scores after treatment with tPA" 02/01/2002 - "There was a significant improvement in National Institutes of Health Stroke Scale scores after treatment" 11/01/1991 - "BACKGROUND: To judge the efficacy of new, putative stroke therapies, we need a method to measure neurological deficit accurately in groups of patients before and after treatment" 12/01/1998 - "Ten patients (77%) showed improvement in the National Institutes of Health (NIH) stroke score after treatment" 08/01/2008 - "The trial was stopped in 2007 at the second interim analysis after treatment resulted in a reduction in stroke and total mortality" Order ALL the reference details at left...